Evidence map›Paper›PMID 27245446›Full record

ArticleMalaria journal2016

The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity.

Sidhartha Chaudhury, Christian F Ockenhouse, Jason A Regules, Sheetij Dutta, Anders Wallqvist, Erik Jongert, Norman C Waters, Franck Lemiale, Elke Bergmann-Leitner

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Humoral Immune Responses toInfection and drug resistance · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Sidhartha ChaudhuryBiotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, USA.
Christian F OckenhousePATH Malaria Vaccine Initiative, Washington, DC, USA.
Jason A RegulesDepartment of Clinical Research, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD, USA.
Sheetij DuttaMalaria Vaccine Branch, U.S. Military Malaria Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, 3W53, Silver Spring, MD, 20910, USA.
Anders WallqvistBiotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, USA.
Erik JongertGSK Vaccine, Rixensart, Belgium.
Norman C WatersMalaria Vaccine Branch, U.S. Military Malaria Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, 3W53, Silver Spring, MD, 20910, USA.
Franck LemialePATH Malaria Vaccine Initiative, Washington, DC, USA.
Elke Bergmann-LeitnerMalaria Vaccine Branch, U.S. Military Malaria Research Program, Walter Reed Army Institute of Research, 503 Robert Grant Ave, 3W53, Silver Spring, MD, 20910, USA. elke.s.bergmannleitner.civ@mail.mil.
Walter Reed Army Institute of Research · USU.S. President's Malaria Initiative · USGlaxoSmithKline (Belgium) · BETelemedicine & Advanced Technology Research Center · USUnited States Army Medical Research and Development Command · USUnited States Army Medical Research Institute of Infectious Diseases · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent vaccine studies have shown that the magnitude of an antibody response is often insufficient to explain efficacy, suggesting that characteristics regarding the quality of the antibody response, such as its fine specificity and functional activity, may play a major role in protection. Previous studies of the lead malaria vaccine candidate, RTS,S, have shown that circumsporozoite protein (CSP)-specific antibodies and CD4(+) T cell responses are associated with protection, however the role of fine specificity and biological function of CSP-specific antibodies remains to be elucidated. Here, the relationship between fine specificity, opsonization-dependent phagocytic activity and protection in RTS,S-induced antibodies is explored.

methodsA new method for measuring the phagocytic activity mediated by CSP-specific antibodies in THP-1 cells is presented and applied to samples from a recently completed phase 2 RTS,S/AS01 clinical trial. The fine specificity of the antibody response was assessed using ELISA against three antigen constructs of CSP: the central repeat region, the C-terminal domain and the full-length protein. A multi-parameter analysis of phagocytic activity and fine-specificity data was carried out to identify potential correlates of protection in RTS,S.

resultsResults from the newly developed assay revealed that serum samples from RTS,S recipients displayed a wide range of robust and repeatable phagocytic activity. Phagocytic activity was correlated with full-length CSP and C-terminal specific antibody titres, but not to repeat region antibody titres, suggesting that phagocytic activity is primarily driven by C-terminal antibodies. Although no significant difference in overall phagocytic activity was observed with respect to protection, phagocytic activity expressed as 'opsonization index', a relative measure that normalizes phagocytic activity with CS antibody titres, was found to be significantly lower in protected subjects than non-protected subjects.

conclusionsOpsonization index was identified as a surrogate marker of protection induced by the RTS,S/AS01 vaccine and determined how antibody fine specificity is linked to opsonization activity. These findings suggest that the role of opsonization in protection in the RTS,S vaccine may be more complex than previously thought, and demonstrate how integrating multiple immune measures can provide insight into underlying mechanisms of immunity and protection.

Indexed as

PhagocytosisAntibodies, ProtozoanCell LineCohort StudiesEnzyme-Linked Immunosorbent AssayHumansMalariaMalaria VaccinesOpsonin ProteinsVaccines, SyntheticAntibodies, ProtozoanMalaria VaccinesOpsonin ProteinsRTS,S-AS01 vaccineVaccines, SyntheticAntibodyEpitopeMalariaPhagocytosisProtection

Identifiers

PMID27245446
PMCPMC4886414
OpenAlexW2414241210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.